Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 2/20 | 0.38 |
| ▸ | CTSB | P07858 | 2/20 | 0.38 |
| ▸ | CTSK | P43235 | 2/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3338802 | 0.85 | TSHR (0.50) | TSHRKDM4EPOLBSGMS2CHRM3 | |
| SCHEMBL5442780 | 0.82 | IDO1 (0.41) | CHRM3MAOBIDO1NAAA | |
| SCHEMBL5529079 | 0.82 | KDM4E (0.53) | TSHRKDM4EPOLBSGMS2CHRM3 | |
| SCHEMBL23750641 | 0.81 | TSHR (0.50) | TSHRKDM4EPOLBCA1TACR1 | |
| SCHEMBL350845 | 0.81 | TSHR (0.50) | TSHRKDM4EPOLBSGMS2CA1 | |
| SCHEMBL6043011 | 0.80 | TSHR (0.58) | TSHRKDM4EPOLBCA1TACR1 | |
| SCHEMBL17019123 | 0.80 | TSHR (0.48) | TSHRKDM4EPOLBCA1TACR1 | |
| SCHEMBL27037968 | 0.80 | MAOB (0.60) | KDM4EPOLBMAOB | |
| SCHEMBL20267540 | 0.79 | TSHR (0.47) | TSHRKDM4EPOLBSGMS2MAOB | |
| SCHEMBL20230845 | 0.79 | TSHR (0.47) | TSHRKDM4EPOLBSGMS2MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7737166-B2 | Antifungal bicyclic hetero ring compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-06-15 | — | — | US | disclosed |
| US-20090143353-A1 | such as 2-tert-Butyl-7-[(3S)-3-(dimethylamino)pyrrolidin-1-yl]-5-methyl-6-phenyl-1,3-benzoxazole-4-carbonitrile hydrochloride, a 1,6-beta-glucan synthetase inhibitor having potent growth inhibition, used treating a fungal infections; fungicides | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-06-04 | — | — | US | disclosed |
| EP-1932837-A1 | BICYCLO HETEROCYCLIC COMPOUND HAVING ANTIFUNGAL ACTION | Daiichi Sankyo Company, Limited (JP) | 2008-06-18 | — | — | EP | disclosed |
| US-20070191395-A1 | Heterocyclic compounds having antifungal activity | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1717238-A1 | FUNGICIDAL HETEROCYCLIC COMPOUNDS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-11-02 | — | — | EP | disclosed |
| EP-0748800-B1 | Pyrimidinedione, pyrimidinetrione, triazinedione derivatives as alpha-1-adrenergic receptor antagonists | HOFFMANN LA ROCHE (CH) | 2001-05-09 | — | — | EP | disclosed |
| US-5859014-A | USEFUL IN TREATMENT OF DISEASES INVOLVING DIRECTLY OR INDIRECTLY AN OBSTRUCTION OF THE LOWER URINARY TRACT, SUCH ASBENIGN PROSTATE HYPERPLASIA | SYNTEX (U.S.A.) INC. (US) | 1999-01-12 | — | — | US | disclosed |
| CN-1149051-A | Pyrimidinedione, pyrimidinetrione, triazinedione, tetrahydroquinazolinedione derivatives as alpha1 adrenergic receptor antagonists | HOFFMANN LA ROCHE (CH) | 1997-05-07 | — | — | CN | disclosed |
| EP-0748800-A2 | Pyrimidinedione, pyrimidinetrione, triazinedione, tetrahydroquinazolinedione derivatives as alpha-1-adrenergic receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 1996-12-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143353-A1 | such as 2-tert-Butyl-7-[(3S)-3-(dimethylamino)pyrrolidin-1-yl]-5-methyl-6-phenyl-1,3-benzoxazole-4-carbonitrile hydrochloride, a 1,6-beta-glucan synthetase inhibitor having potent growth inhibition, used treating a fungal infections; fungicides | CTPS1, TPP1, STS | TSHR 3879/4885KDM4E 1665/4885POLB 1706/4885 |
| US-20070191395-A1 | Heterocyclic compounds having antifungal activity | ERG28, MANBA, MAN2B1 | TSHR 4794/4885KDM4E 3019/4885POLB 2910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.